Maxim Group Begins Coverage on Hancock Jaffe Laboratories (NASDAQ:HJLI)

Maxim Group started coverage on shares of Hancock Jaffe Laboratories (NASDAQ:HJLI) in a report published on Tuesday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating and a $3.00 price objective on the stock.

HJLI has been the topic of several other research reports. Zacks Investment Research cut shares of Hancock Jaffe Laboratories from a buy rating to a hold rating in a research report on Wednesday, June 26th. ValuEngine raised shares of Hancock Jaffe Laboratories from a hold rating to a buy rating in a research report on Thursday, August 1st.

Shares of HJLI stock remained flat at $$1.02 during trading hours on Tuesday. 15,718 shares of the stock traded hands, compared to its average volume of 135,197. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.60 and a current ratio of 2.46. Hancock Jaffe Laboratories has a twelve month low of $0.87 and a twelve month high of $3.45. The stock has a 50 day simple moving average of $1.04. The firm has a market cap of $18.28 million, a P/E ratio of -0.53 and a beta of 1.34.

Hancock Jaffe Laboratories (NASDAQ:HJLI) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.14. Hancock Jaffe Laboratories had a negative net margin of 5,161.19% and a negative return on equity of 207.10%. The business had revenue of $0.03 million for the quarter, compared to analysts’ expectations of $0.03 million.

A hedge fund recently bought a new stake in Hancock Jaffe Laboratories stock. Jane Street Group LLC acquired a new position in shares of Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 31,692 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.27% of Hancock Jaffe Laboratories as of its most recent SEC filing. Hedge funds and other institutional investors own 1.10% of the company’s stock.

Hancock Jaffe Laboratories Company Profile

Hancock Jaffe Laboratories, Inc, a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease.

Featured Article: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with's FREE daily email newsletter.